A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with mild Alzheimer's disease (AD) or amnestic mild cognitive impairment (amnestic MCI).

Trial Profile

A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with mild Alzheimer's disease (AD) or amnestic mild cognitive impairment (amnestic MCI).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs AQW 051 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2009 Actual patient number (54), additional location South Africa added as reported by ClinicalTrials.gov.
    • 12 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top